1h Free Analyst Time
The insomnia therapeutics market is forecasted to grow by USD 1.10 billion during 2023-2028, accelerating at a CAGR of 5.72% during the forecast period. The report on the insomnia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of insomnia, technological advancements in diagnostics and treatment, and rising healthcare expenditure and insurance coverage.
The insomnia therapeutics market is segmented as below:
By Type
- Drug
- Devices
By Distribution Channel
- Prescription
- OTC
By Geographical Landscape
- North America
- Asia
- Europe
- Rest of World (ROW)
The report on the insomnia therapeutics market covers the following areas:
- Insomnia therapeutics market sizing
- Insomnia therapeutics market forecast
- Insomnia therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global insomnia therapeutics market: Abbott Laboratories, Astellas Pharma Inc., Aurobindo Pharma Ltd., Eisai Co. Ltd., Electromedical Products International Inc., Idorsia Pharmaceuticals Ltd., INNOVATIVE NEUROLOGICAL DEVICES LLC, Mallinckrodt Plc, MEDICE Arzneimittel Putter GmbH and Co. KG, Merck and Co. Inc., Minerva Neurosciences Inc., Neurim Pharmaceuticals Ltd., Pfizer Inc., Questex LLC, Sanofi SA, Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increased focus on non-pharmacological treatments."
According to the report, one of the major drivers for this market is the increasing prevalence of insomnia.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Astellas Pharma Inc.
- Aurobindo Pharma Ltd.
- Eisai Co. Ltd.
- Electromedical Products International Inc.
- Idorsia Pharmaceuticals Ltd.
- INNOVATIVE NEUROLOGICAL DEVICES LLC
- Mallinckrodt Plc
- MEDICE Arzneimittel Putter GmbH and Co. KG
- Merck and Co. Inc.
- Minerva Neurosciences Inc.
- Neurim Pharmaceuticals Ltd.
- Pfizer Inc.
- Questex LLC
- Sanofi SA
- Sumitomo Pharma Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Vanda Pharmaceuticals Inc.
- Viatris Inc.
